Atlas Trials

A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

Clinical trial NCT03825705 · UNKNOWN

Trial details

NCT number
NCT03825705
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
Start date
2019-04-23
Primary completion
2021-01-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.